title: Bioavailability and half-life of decabromodiphenyl ether (BDE-209) in rat.
abstract: 1. The absorption of the flame retardant decabromodiphenyl ether (BDE-209) has been shown by its detection in human plasma, but reported experimental data on its determined in rat, and qualitative analyses by GC/MS of metabolites in plasma were performed. The relative amount of phenolic metabolites was determined in a rat plasma sample obtained after administration of radiolabelled BDE-209. 2. The bioavailability of parent BDE-209 was calculated to be about 26% in rat. The concentrations of phenolic radioactivity in plasma 3 and 7 days after dosing were four times higher than those of the neutral compounds, i.e. parent compound, indicating absorption in rat are inconsistent. The bioavailability and half-life were therefore that total absorption was higher than 26%. 3. Thirteen phenolic metabolites were determined in the plasma and the major phenolic metabolites were characterized as a hydroxy-octaBDE, a hydroxy-nonaBDE and a hydroxy-methoxy-hexaBDE (guaiacol-type). The exposure to the phenolic metabolites seemed higher than the parent compound, BDE-209. 4. The initial elimination phase in plasma t1/2alpha for BDE-209 was 2 h, implying a rapid distribution of BDE-209 to well-perfused tissues. The distribution volume at steady state was 1.4 l kg-1, implying a low tendency for distribution to adipose tissue. The terminal t1/2 for BDE-209 in the intravenously dosed rat was calculated as 2.5 days (58 h).
authors.affiliation: Department of Environmental Chemistry, Stockholm University, SE-106 91 Stockholm, Sweden.
authors.forename: A
authors.initials: A
authors.lastname: Sandholm
authors.forename: B-M
authors.initials: BM
authors.lastname: Emanuelsson
authors.forename: E Klasson
authors.initials: EK
authors.lastname: Wehler
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001682:Biological Availability; D001711:Biotransformation; D001969:Bromobenzenes / Q000493:pharmacokinetics*; D005411:Flame Retardants / Q000493:pharmacokinetics*; D008401:Gas Chromatography-Mass Spectrometry; D006207:Half-Life; D055768:Halogenated Diphenyl Ethers; D007275:Injections, Intravenous; D008297:Male; D010647:Phenyl Ethers; D011075:Polybrominated Biphenyls; D051381:Rats; D017207:Rats, Sprague-Dawley; D012997:Solvents; D014018:Tissue Distribution
chemical_list: D001969:Bromobenzenes; D005411:Flame Retardants; D055768:Halogenated Diphenyl Ethers; D010647:Phenyl Ethers; D011075:Polybrominated Biphenyls; D012997:Solvents; C010902:decabromobiphenyl ether